fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Mutual Funds » Nippon India PHARMA Fund

Nippon India PHARMA Fund - G

NAV  ₹499.917 ↑ 2.55  (0.51 %) as on 19 May 25

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 20.5% since its launch.  Ranked 35 in Sectoral category.  Return for 2024 was 34% , 2023 was 39.2% and 2022 was -9.9% .

Below is the key information for Nippon India Pharma Fund

NAV as on 19 May 25₹499.917 ↑ 2.55  (0.51 %)
Net Assets (AUM) as on 30 Apr 2025 ₹8,260 Cr.
Launch Date5 Jun 2004
CategoryEquity - Sectoral
Rating
TypeOpen Ended Fund
RiskHigh
AMCNippon Life Asset Management Ltd.
Alpha Ratio-1.9
Expense Ratio1.88 %
Sharpe Ratio0.539
Information Ratio-0.22
BenchmarkNot Available
Min Investment ₹5,000
Min SIP Investment ₹100
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 19 May 25

DurationReturns
1 Month 2.6%
3 Month 6.2%
6 Month 0.1%
1 Year 15.1%
3 Year 23.4%
5 Year 23.2%
10 Year
15 Year
Since launch 20.5%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

YearReturns
2024 34%
2023 39.2%
2022 -9.9%
2021 23.9%
2020 66.4%
2019 1.7%
2018 3.6%
2017 7.6%
2016 -10.6%

Growth of 10k Over Years

DateValue
30 Apr 20₹10,000
30 Apr 21₹15,389
30 Apr 22₹15,981
30 Apr 23₹15,783
30 Apr 24₹23,851
30 Apr 25₹27,660

Asset Allocation

Asset ClassValue
Cash0.29%
Equity99.71%

Sector Allocation

SectorValue
Health Care99.71%

Top Securities Holdings / Portfolio

Holdings/Securities

NameGlobal IndustryHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
Drug Manufacturers - Specialty & Generic14%₹1,146 Cr6,256,349
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
Drug Manufacturers - Specialty & Generic10%₹791 Cr1,298,808
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257
Drug Manufacturers - Specialty & Generic6%₹521 Cr2,483,991
↓ -414,135
Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 500087
Drug Manufacturers - Specialty & Generic6%₹496 Cr3,200,000
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP
Medical Care Facilities5%₹453 Cr648,795
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY
Drug Manufacturers - Specialty & Generic5%₹434 Cr3,662,170
GlaxoSmithKline Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Aug 22 | GLAXO
Drug Manufacturers - General4%₹300 Cr1,011,921
Medplus Health Services Ltd (Healthcare)
Equity, Since 30 Nov 22 | 543427
Pharmaceutical Retailers4%₹292 Cr3,627,277
Vijaya Diagnostic Centre Ltd (Healthcare)
Equity, Since 30 Sep 21 | 543350
Diagnostics & Research3%₹283 Cr2,831,564
Abbott India Ltd (Healthcare)
Equity, Since 31 May 11 | ABBOTINDIA
Drug Manufacturers - Specialty & Generic3%₹267 Cr88,883
↓ -2,050
1 - 10 of 41
Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Fund Managers

NameSinceTenure
Sailesh Raj Bhan1 Apr 0520.09 Yr.
Kinjal Desai25 May 186.94 Yr.

Custodians

CompanyAddress
Deutsche Bank AGDeutsche Bank AG,Kodak House, 22, D.N. Road,

Registrar & Transfer Agent

KFin Technologies Ltd
Address138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat
FAXN.A
EmailN.A

Administrator Companies

CompanyAddress
Nippon India Mutual Fund9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

CompanyAddress
Haribhakti & Co. Chartered Accountants42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and PlanNAV6 Month1 Year3 Year5 Year
Nippon India Pharma Fund
Normal Dividend, Payout
₹116.518
↑ 0.59
-0.68 %14.15 %22.75 %25.73 %
Nippon India Pharma Fund
Normal Dividend, Reinvestment
₹116.518
↑ 0.59
-0.68 %14.15 %22.75 %25.73 %
Nippon India Pharma Fund
Growth
₹499.917
↑ 2.55
0.14 %15.1 %23.39 %23.17 %
Data as on 19 May 25

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.